産後うつ病 - 市場考察、疫学、市場予測（2032年）

主なハイライト

• 米国が2022年に主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）の市場規模全体の64.6％を占めました。
• 病態生理学を確立するための研究開発の増加や診断における最近の進歩が、市場に有利な機会を与えています。

市場

• スペインが2022年に主要7市場の市場規模の最大2%を占めました。
• 欧州4ヶ国・英国では、英国が最大の市場規模を占め、欧州4ヶ国全体の市場規模の最大33.9%を占めました。

当レポートでは、産後うつ病（PPD）の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 産後うつ病（PPD）市場の概要

• 産後うつ病（PPD）の市場シェア分布：治療法別（2019年）
• 産後うつ病（PPD）の市場シェア分布：治療法別（2032年）

第4章 産後うつ病（PPD）のエグゼクティブサマリー

第5章 主な出来事

第6章 疾患の背景と概要

• イントロダクション
• 臨床症状
• 危険因子
• 病因
• 診断とスクリーニング

第7章 治療と管理

• 抗うつ薬
• 心理的・心理社会的治療
• 非薬物療法
• ホルモン療法
• 治療アルゴリズム
• Unicareによる治療ガイドライン
• NICEによる治療ガイドライン

第8章 調査手法

第9章 疫学と患者数

• 主な調査結果
• 前提条件と根拠
• 主要7市場の産後うつ病（PPD）と診断された有病人口
• 米国の疫学シナリオ
  • 米国の産後うつ病（PPD）と診断された有病人口
• 欧州4ヶ国・英国の疫学シナリオ
  • 欧州4ヶ国・英国の産後うつ病（PPD）と診断された有病人口
• 日本の疫学シナリオ
  • 日本の産後うつ病（PPD）と診断された有病人口

第10章 ペイシェントジャーニー

第11章 上市済みの治療法

• キークロス
• ZULRESSO: Sage Therapeutics

第12章 新しい治療法

• キークロス
• SAGE-217/BIIB-125: Sage Therapeutics/Biogen
• Ganaxolone: Marinus Pharmaceuticals
• LPCN 1154: Lipocine
• BRII-296: Brii Biosciences Limited

第13章 産後うつ病（PPD）：主要7市場の分析

• 主な調査結果
• 市場見通し
• 主な市場予測の前提条件
• 主要7市場の産後うつ病（PPD）の総市場規模
• 主要7市場の産後うつ病（PPD）の市場規模：治療法別
• 米国の市場規模
  • 米国の産後うつ病（PPD）の総市場規模
  • 米国の産後うつ病（PPD）の市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国の産後うつ病（PPD）の総市場規模
  • 欧州4ヶ国・英国の産後うつ病（PPD）の市場規模：治療法別
• 日本の市場規模
  • 日本の産後うつ病（PPD）の総市場規模
  • 日本の産後うつ病（PPD）の市場規模：治療法別

第14章 KOLの見解

第15章 SWOT分析

第16章 アンメットニーズ

第17章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第18章 付録

第19章 DelveInsightのサービス内容

第20章 免責事項

第21章 DelveInsightについて

List of Tables

• Table 1: Summary of Postpartum Depression (PPD), Market, and Epidemiology (2019-2032)
• Table 2: Key Events
• Table 3: Key Recommendations for Practice
• Table 4: Depression in DSM Evolution
• Table 5: Depression in DSM
• Table 6: DSM-V Diagnostic Criteria for Major Depressive Episode
• Table 7: Commercially Available Antidepressants to Use During Pregnancy or Breastfeeding
• Table 8: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the 7MM, in Thousand (2019-2032)
• Table 9: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United States, in Thousand (2019-2032)
• Table 10: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in EU4 and the UK, in Thousand (2019-2032)
• Table 11: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Japan, in Thousand (2019-2032)
• Table 12: Comparison of Marketed Drugs
• Table 13: Patents for ZULRESSO
• Table 14: ZULRESSO (brexanolone), Clinical Trial Description, 2023
• Table 15: Comparison of Emerging Drugs Under Development
• Table 16: Zuranolone, Clinical Trial Description, 2023
• Table 17: SKYLARK Study Summary Results
• Table 18: Ganaxalone; Clinical Trial Description, 2023
• Table 19: Key Market Forecast Assumptions for Zuranolone
• Table 20: Total Market Size of Postpartum Depression (PPD) in the 7MM, in USD million (2019-2032)
• Table 21: Market Size of Postpartum Depression (PPD) by Therapies in the 7MM, in USD million (2019-2032)
• Table 22: Total Market Size of Postpartum Depression (PPD) in the United States, in USD million (2019-2032)
• Table 23: Market Size of Postpartum Depression (PPD) by Therapies in the United States, in USD million (2019-2032)
• Table 24: Total Market Size of Postpartum Depression (PPD) in EU4 and the UK, in USD million (2019-2032)
• Table 25: Market Size of Postpartum Depression (PPD) by Therapies in EU4 and the UK, in USD million (2019-2032)
• Table 26: Total Market Size of Postpartum Depression (PPD) in Japan, in USD million (2019-2032)
• Table 27: Market Size of Postpartum Depression (PPD) by Therapies in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Pathogenesis of PPD
• Figure 2: Pharmacological Treatment of PPD
• Figure 3: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the 7MM (2019-2032)
• Figure 4: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United States (2019-2032)
• Figure 5: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in EU4 and the UK (2019-2032)
• Figure 6: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Japan (2019-2032)
• Figure 7: Total Market Size of Postpartum Depression (PPD) in the 7MM (2019-2032)
• Figure 8: Market Size of Postpartum Depression (PPD) by Therapies in the 7MM, in USD million (2019-2032)
• Figure 9: Total Market Size of Postpartum Depression (PPD) in the United States, in USD million (2019-2032)
• Figure 10: Market Size of Postpartum Depression (PPD) by Therapies in the United States, in USD million (2019-2032)
• Figure 11: Total Market Size of Postpartum Depression (PPD) in EU4 and the UK, in USD million (2019-2032)
• Figure 12: Market Size of Postpartum Depression (PPD) by Therapies in EU4 and the UK, in USD million (2019-2032)
• Figure 13: Total Market Size of Postpartum Depression (PPD) in Japan, in USD million (2019-2032)
• Figure 14: Market Size of Postpartum Depression (PPD) by Therapies in Japan, in USD million (2019-2032)
• Figure 15: Unmet Needs
• Figure 16: Health Technology Assessment
• Figure 17: Reimbursement Process in Germany
• Figure 18: Reimbursement Process in France
• Figure 19: Reimbursement Process in Italy
• Figure 20: Reimbursement Process in Spain
• Figure 21: Reimbursement Process in the United Kingdom
• Figure 22: Reimbursement Process in Japan

Key Highlights:

• Postpartum depression (PPD) is the most common non-psychotic complication of childbearing affecting approximately 10-15% of women. People with postpartum depression experience emotional highs and lows, frequent crying, fatigue, guilt, and anxiety, and may have trouble caring for their baby.
• It usually begins within 1-12 months after delivery. Genetics, hormonal, psychological, and social life stressors play a role in developing PPD. Women with a history of depression and other mental health conditions, various face a higher risk of PPD.
• Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy effectively treat PPD. Classes of medications are being prescribed for PPD as off-label therapies, such as selective serotonin reuptake inhibitors (SSRIs), a serotonin-norepinephrine reuptake inhibitors (SNRI). In March 2019, the US FDA approved ZULRESSO (brexanolone/SAGE-547), the first drug to treat adult PPD.
• A few therapies that are being investigated for the treatment of PPD include Zuranolone (Sage Therapeutics), Ganaxolone (Marinus Pharmaceuticals), LPCN 1154 (Lipocine), and BRII-296 (Brii Biosciences).
• As far as the epidemiology of postpartum depression is concerned, in 2022, it was found that the United States accounted for ~55% of the total diagnosed prevalent cases of maternal postpartum depression in the 7MM.
• The market size captured by the United States was found to be the largest among the 7MM countries. In 2022, it was found that the United States accounted for ~64.6% of the total market size captured by the 7MM region.
• The lack of a standardized screening method for depression, consistent cut-off scores on instruments, inconsistent data collection points, and lack of formal diagnosis based on diagnostic criteria challenge psychiatrists to establish a definitive PPD. However, increasing research and development to establish the pathophysiology and recent advancement in the diagnosis gives a lucrative opportunity for the PPD market.
• The effects of postpartum depression on the mother, her marital relationship, and her children make it an important condition to diagnose, treat, and prevent. Enhancing healthcare services, raising awareness, and supporting individuals with PPD are essential steps toward addressing the challenges associated with this disease.

Report Summary

• The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
• The report also encompasses a comprehensive analysis of the postpartum depression market, providing an in-depth examination of its historical and projected market size (2019-2032). It also includes the market share of therapies, along with detailed assumptions and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
• The report includes qualitative insights that provide an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM postpartum depression market.

Market

There are various key players currently leading the treatment landscape of postpartum depression, such as Sage Therapeutics. The details of the country and therapy-wise market size have been provided below.

• In 2022, the United States accounted for the largest market size among the 7MM countries, making ~64.6% of the total market size of the 7MM.
• Among the 7MM countries, Spain had the market size in 2022, accounting for ~2% of the market size in the 7MM region.
• In EU4 and the UK region, the UK accounted for the largest market size, making up ~33.9% of the total market size of the EU4 region.

Postpartum Depression Drug Chapters

The section dedicated to drugs in the postpartum depression report provides an in-depth evaluation of marketed therapies and the late-stage pipeline drugs (Phase III and Phase II) related to postpartum depression.

The drug chapters section provides valuable information on various aspects related to clinical trials of postpartum depression, including specific details, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting postpartum depression.

Marketed Therapies

ZULRESSO (brexanolone): Sage Therapeutics

ZULRESSO (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA), a receptor-positive modulator indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility.

Emerging Therapies

SAGE-217/BIIB-125: Sage Therapeutics/Biogen

Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression.

Ganaxolone: Marinus Pharmaceuticals

Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD.

Note: Detailed assessment will be provided in the final report of postpartum depression…

Postpartum Depression Market Outlook

Postpartum depression (PPD) is a serious but treatable medical illness that involves extreme sadness, emotional liability, indifference and/or anxiety, and changes in energy, sleep, and appetite and carries risks for the mother and the newborn child. PPD usually starts within the first month or any time within the first year after childbirth and can last from weeks to months.

Treatments include antidepressant medications and the new upcoming therapeutic strategies that work on the principle of GABAA receptor modulation. The medical management for PPD comprises several aspects, such as interventions for depression, anxiety disorders, alcohol and drug abuse, and psychological interventions for eating disorders. The treatment strategy also encompasses psychological and psychosocial treatments and non-pharmacologic treatments. Besides, the medical care of a PPD patient and his family is incomplete without providing a support system for their psychosocial well-being.

Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the treatment for PPD. They are being used as off-label drugs for the treatment of PPD. The current market consists of only one approved product ZULRESSO (brexanolone/SAGE-547), to treat patients with PPD. ZULRESSO, which is marketed by Sage Therapeutics, was approved by the US FDA in March 2019.

Psychotherapy, such as cognitive behavioral therapy, is recommended as first-line treatment for mild-to-moderate PPD due to rapid efficacy, lack of adverse effects on mother and infant, and no impact on breastfeeding. Pharmacotherapy, either individually or in combination with psychotherapy, is advised for moderate-to-severe PPD. Selective serotonin inhibitors, particularly sertraline, and citalopram, are recommended due to their minimal effects on breastfeeding.

In addition to improving currently available treatments and increasing access to those treatments, novel therapeutics are needed that specifically target the underlying pathophysiology of the disorder. The patient burden will increase in the coming times, and approval of the emerging drug will expand the market. Therefore, the overall market size will increase, which could be a better investment therapy area.

Postpartum Depression Disease Understanding and Treatment

Postpartum Depression Overview

Postpartum depression (PPD) is the most common non-psychotic complication of childbearing affecting approximately 10-15% of women. It can interfere with normal maternal-infant bonding and adversely affect acute and long-term child development. Women with a history of depression and other mental health conditions, various face a higher risk of PPD. The signs and symptoms of PPD include depressed mood, loss of interest, changes in sleep patterns, change in appetite, feelings of worthlessness, inability to concentrate, and suicidal ideation. Women may also experience anxiety. Patients having PPD may also have psychotic symptoms, which include delusions and hallucinations.

Postpartum Depression Diagnosis

Postpartum depression is diagnosed when at least five depressive symptoms are present for at least 2 weeks. In the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), postpartum depression is considered when a patient has a major depressive episode along with the peripartum onset, and it is not mentioned as a separate disease. Screening for PPD can be done 2-6 months after childbirth. Women with postpartum depression should also be assessed for manic features. Several screening tools are available, and one of the most frequently used is the Edinburgh Postnatal Depression Scale (EPDS). The diagnosis of PPD should be strongly considered in women who score above 12 on the EPDS scale.

Further details related to country-based variations are provided in the report…

Postpartum Depression Treatment

Postpartum depression can be treated with medication and counseling. Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy effectively treat PPD. Other treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga. Other classes of medications are being prescribed for PPD as off-label therapies. One such class of medication is selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, sertraline, and others. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, has also been useful in treating PPD. As with treatment-refractory major depression in the general population, electroconvulsive therapy (ECT) is an option for depressed postpartum women who do not respond to antidepressant medication or who have severe or psychotic symptoms.

Further details related to treatment and management are provided in the report…

Postpartum Depression Epidemiology

The postpartum depression epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Maternal Postpartum Depression (PPD) Cases in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

• In 2022, the total diagnosed prevalent maternal postpartum depression (PPD) cases in the United States were ~716,000 which is projected to increase during the forecast period (2023-2032).
• The total diagnosed prevalent maternal postpartum depression (PPD) cases in EU4 and the UK were ~461,000 in 2022. The cases are projected to increase during the forecast period (2023-2032).
• The total diagnosed prevalent maternal postpartum depression (PPD) cases in Japan were ~125,300 in 2022.

KOL Views

In order to stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of postpartum depression, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7 Major Markets (7MM). We contacted institutions such as the University of Nevada, University of Valencia, UConn Health Center, Strasbourg University, and others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the postpartum depression market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for postpartum depression, one of the most important primary endpoints was depressive symptoms measured by the HAM-D total score. Based on these, the overall efficacy is evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Postpartum Depression Report Insights

• Patient Population
• Therapeutic Approaches
• Postpartum Depression Market Size and Trends
• Existing Market Opportunity

Postpartum Depression Report Key Strengths

• Ten-year Forecast
• The 7MM Coverage
• Postpartum Depression Epidemiology Segmentation
• Key Cross Competition

Postpartum Depression Report Assessment

• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis)

Key Questions

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in postpartum depression management recommendations?
• Would research and development advances pave the way for future tests and therapies for postpartum depression?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of postpartum depression?
• What kind of uptake the new therapies are going to witness in the coming years in postpartum depression patients?

Table of Contents

1. Key Insights

2. Report Introduction

3. Postpartum Depression Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Postpartum Depression (PPD) by therapies in 2019
• 3.2. Market Share (%) Distribution of Postpartum Depression (PPD) by therapies in 2032

4. Executive Summary of Postpartum depression (PPD)

5. Key events

6. Disease Background and Overview

• 6.1. Introduction
• 6.2. Clinical Presentation
• 6.3. Risk Factors
• 6.4. Pathogenesis
• 6.5. Diagnosis and Screening
  • 6.5.1. Diagnostic Criteria

7. Treatment and Management

• 7.1. Antidepressant Medication
• 7.2. Psychological and Psychosocial Treatments
• 7.3. Non-pharmacologic Treatments
• 7.4. Hormone Therapy
• 7.5. Treatment Algorithm
• 7.6. Treatment Guidelines by Unicare
• 7.7. Treatment Guidelines by the National Institute for Health and Care Excellence (NICE)

8. Methodology

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Diagnosed Prevalent Population of Postpartum Depression in the 7MM
• 9.4. Epidemiology Scenario in the United States
  • 9.4.1. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United States
• 9.5. Epidemiology Scenario in EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in EU4 and the UK
• 9.6. Epidemiology Scenario in Japan
  • 9.6.1. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Japan

10. Patient Journey

11. Marketed Therapies

• 11.1. Key Cross
• 11.2. ZULRESSO: Sage Therapeutics
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Clinical Developmental Activities
  • 11.2.5. Safety and Efficacy

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. SAGE-217/BIIB-125: Sage Therapeutics/Biogen
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and efficacy
• 12.3. Ganaxolone: Marinus Pharmaceuticals
  • 12.3.1. Product Description
  • 12.3.2. Other Developmental Activity
  • 12.3.3. Clinical Development
  • 12.3.4. Safety and efficacy
• 12.4. LPCN 1154: Lipocine
  • 12.4.1. Product Description
  • 12.4.2. Other Developmental Activity
• 12.5. BRII-296: Brii Biosciences Limited
  • 12.5.1. Product Description
  • 12.5.2. Clinical Development
  • 12.5.3. Safety and efficacy

13. Postpartum Depression (PPD): Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Key Market Forecast Assumptions
• 13.4. Total Market Size of Postpartum Depression (PPD) in the 7MM
• 13.5. Market Size of Postpartum Depression (PPD) by Therapies in the 7MM
• 13.6. The United States Market Size
  • 13.6.1. Total Market Size of Postpartum Depression (PPD) in the United States
  • 13.6.2. Market Size of Postpartum Depression (PPD) by Therapies in the United States
• 13.7. EU4 and the UK Market Size
  • 13.7.1. Total Market Size of Postpartum Depression (PPD) in EU4 and the UK
  • 13.7.2. Market Size of Postpartum Depression (PPD) by Therapies in EU4 and the UK
• 13.8. Japan Market Size
  • 13.8.1. Total Market Size of Postpartum Depression (PPD) in Japan
  • 13.8.2. Market Size of Postpartum Depression (PPD) by Therapies in Japan

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Market Access and Reimbursement

• 17.1. The United States
  • 17.1.1. Centre for Medicare and Medicaid Services (CMS)
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. The United Kingdom
• 17.3. Japan
  • 17.3.1. MHLW

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight